Vegzelma added as a non-preferred bevacizumab product

CarePartners of Connecticut applies a step therapy protocol for bevacizumab products, with Mvasi and Zirabev considered preferred products and Avastin and Alymsys (and their biosimilars) considered non-preferred.

The drug Vegzelma (bevacizumab-abcd), a biosimilar of Avastin that was approved by the FDA in late September 2022, has been added as a non-preferred drug. Coverage of Vegzelma requires prior authorization, and patients are required to have first tried one of the preferred products before coverage will be approved for Vegzelma.

For complete information, including covered indications and criteria, step therapy requirements, and coding, please refer to CarePartners of Connecticut’s updated Medical Necessity Guidelines for Bevacizumab Products. In addition, we’ve updated the Medical Necessity Guidelines for Medicare Part B Step Therapy to reflect this change.